Document is current
Any future updates will be listed below
-
Authors
Fornaro, Michele https://orcid.org/0000-0002-9647-0853
Di Lorenzo, Chiara
Nunez, Nicolas
Miola, Alessandro
Calati, Raffaella https://orcid.org/0000-0001-8130-437X
Carvalho, André Ferrer https://orcid.org/0000-0002-2500-5671
Steardo, Luca Jr.
Stubbs, Brendon
Mischoulon, David https://orcid.org/0000-0001-7233-5860
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
Solmi, Marco https://orcid.org/0000-0003-4877-7233
- License Information
-
More Information
Article History
Received: 9 March 2026
Revised: 22 June 2026
Accepted: 6 July 2026
First Online: 1 September 2026
Ethics
Competing interests: MS has received honoraria and/or been a consultant for AbbVie, Angelini, Bausch Health, Boehringer Ingelheim, Pharmascience, Lundbeck, Otsuka, and Teva. CC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Aytu, Axsome, Boehringer-Ingelheim, Brandaris, Bristol-Meyers Squibb, Cardio Diagnostics, Casasco, Cerevel, CNX Therapeutics, Cogstate, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH Research, Hetero, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, Mapi, Maplight, MedInCell, MedLink Global, Merck, Mindpax, Mitsubishi Tanabe Pharmaceuticals, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Neurosterix, NeuShen, Neusignal Therapeutics, Newron, Noven, Novo Nordisk, Orion Pharma, Om, Oruka, Otsuka, Phrenix, PPD Biotech, qCell, Recognify Life Science, Recordati, Relmada, Response Pharmaeutical, Reviva, Roemmers, Rovi, Saladax, Sanofi, Seqirus, Serina, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Syremis, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck, Neurocrine, and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option or stock holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharmaceuticals, MedLink Global, Mindpax, Quantic, Terran. DM has received research support from Nordic Naturals and Heckel Medizintechnik GmbH. He has received honoraria for speaking from the Massachusetts General Hospital Psychiatry Academy. He also works with the MGH Clinical Trials Network and Institute (CTNI), which has received research funding from multiple pharmaceutical companies and NIMH. Other authors have no disclosures in connection with the present report.
